DE60321375D1 - Tumormarker proteine und deren verwendung - Google Patents

Tumormarker proteine und deren verwendung

Info

Publication number
DE60321375D1
DE60321375D1 DE60321375T DE60321375T DE60321375D1 DE 60321375 D1 DE60321375 D1 DE 60321375D1 DE 60321375 T DE60321375 T DE 60321375T DE 60321375 T DE60321375 T DE 60321375T DE 60321375 D1 DE60321375 D1 DE 60321375D1
Authority
DE
Germany
Prior art keywords
cancer
tumour
fluids
marker proteins
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60321375T
Other languages
English (en)
Inventor
John Forsyth Robertson
Catherine Rosamund Graves
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncimmune Ltd
Original Assignee
Oncimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncimmune Ltd filed Critical Oncimmune Ltd
Application granted granted Critical
Publication of DE60321375D1 publication Critical patent/DE60321375D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60321375T 2002-11-14 2003-11-13 Tumormarker proteine und deren verwendung Expired - Lifetime DE60321375D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0226622A GB2395270B (en) 2002-11-14 2002-11-14 Tumour marker proteins and uses thereof
PCT/GB2003/004950 WO2004044590A1 (en) 2002-11-14 2003-11-13 Tumour marker proteins and uses thereof

Publications (1)

Publication Number Publication Date
DE60321375D1 true DE60321375D1 (de) 2008-07-10

Family

ID=9947849

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60321375T Expired - Lifetime DE60321375D1 (de) 2002-11-14 2003-11-13 Tumormarker proteine und deren verwendung

Country Status (14)

Country Link
US (2) US8592169B2 (de)
EP (2) EP1563307B1 (de)
JP (1) JP4759267B2 (de)
AT (1) ATE397217T1 (de)
AU (1) AU2003282245B2 (de)
CA (1) CA2545930C (de)
CY (1) CY1108294T1 (de)
DE (1) DE60321375D1 (de)
DK (1) DK1563307T3 (de)
ES (1) ES2305530T3 (de)
GB (3) GB2424273B (de)
PT (1) PT1563307E (de)
SI (1) SI1563307T1 (de)
WO (1) WO2004044590A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
GB9827228D0 (en) * 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
GB2424273B (en) 2002-11-14 2007-06-27 Univ Nottingham Method for preparing tumour marker protein
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
JP2006242869A (ja) * 2005-03-04 2006-09-14 Kyushu Univ 腫瘍マーカーとしての抗ｎａｓｐ抗体及び抗ｔｍｆ抗体
RU2636532C2 (ru) 2005-05-27 2017-11-23 Онкиммьюн Лимитед Улучшенные способы иммуноанализа
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
WO2006132587A1 (en) * 2005-06-10 2006-12-14 Forskarpatent I Syd Ab Tumour marker in brca2 associated breast cancer
JP5211315B2 (ja) * 2006-07-25 2013-06-12 国立大学法人愛媛大学 腫瘍マーカ、腫瘍診断キットおよび腫瘍マーカの測定方法
CA2663154C (en) * 2006-09-13 2016-02-23 Oncimmune Ltd Improved immunoassay methods
GB2441824A (en) * 2006-09-13 2008-03-19 Oncimmune Ltd Immunoassay method
US8574848B2 (en) 2006-09-13 2013-11-05 Oncimmune Ltd. Immunoassay methods
EP2126562B1 (de) * 2007-02-23 2014-12-31 Physicians Choice Laboratory Services, LLC Auf klinische eingriffe gerichtete diagnostische verfahren
AU2008238258B2 (en) 2007-04-12 2013-05-23 Proteosys Ag Autoimmune regulation of prostate cancer by annexin A3
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
AU2010204741B2 (en) * 2009-01-14 2016-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ratio based biomarkers and methods of use thereof
WO2011116209A2 (en) 2010-03-17 2011-09-22 The Regents Of The University Of Michigan Using phage epitopes to profile the immune response
ES2621874T3 (es) 2010-03-26 2017-07-05 Memorial Sloan-Kettering Cancer Center Anticuerpos para MUC16 y métodos de uso de los mismos
US20130040839A1 (en) * 2011-06-27 2013-02-14 Ambergen, Inc. Method for Diagnosing or Determining the Prognosis of Colorectal Cancer (CRC) Using Novel Autoantigens: Gene Expression Guided Autoantigen Discovery
WO2013016600A2 (en) * 2011-07-28 2013-01-31 The Trustees Of The University Of Pennsylvania Methods and reagents for diagnosing conditions and characterization of tumor cells associated with serous fluids
EP3189332A4 (de) * 2014-09-04 2018-03-21 Provista Diagnostics Inc. Biomarker zur vorhersage von brustkrebs
CN107667120B (zh) 2015-03-17 2022-03-08 纪念斯隆-凯特林癌症中心 抗muc16抗体及其应用
CN113848322A (zh) * 2015-12-11 2021-12-28 善福德健康 用于监测乳腺癌治疗的试剂和方法
GB2600701A (en) 2020-11-04 2022-05-11 Oncimmune Ltd Antibody assay
EP4182693A2 (de) 2020-07-14 2023-05-24 Oncimmune Limited Verwendung einer antigenkombination zum nachweis von autoantikörpern bei lungenkrebs
CN113721021B (zh) * 2021-09-16 2023-07-07 郑州大学 Prkcz自身抗体在食管鳞癌辅助诊断中的应用
GB2622246A (en) 2022-09-08 2024-03-13 Oncimmune Germany Gmbh Antibody assay

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ211453A (en) * 1984-03-22 1989-01-06 Biotechnology Research Enterpr Aryl azides, their preparation and use in the detection, localisation and isolation of polynucleotides
DE3685818T2 (de) 1986-03-10 1993-01-14 Imre Corp Immunkomplextestverfahren.
AU2253688A (en) 1987-07-24 1989-03-01 Xoma Corporation Methods for breast cancer detection
US4937185A (en) * 1987-07-31 1990-06-26 The Ohio State University Research Foundation Detection of circulating antibodies to a cancer marker protein
US5241052A (en) * 1988-03-04 1993-08-31 New England Deaconess Hospital Corporation Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
US7282345B1 (en) * 1989-08-04 2007-10-16 Schering Ag C-erbB-2 external domain: GP75
WO1991006866A2 (en) * 1989-11-03 1991-05-16 Morton Donald L Urinary tumor associated antigen, antigenic subunits uses and methods of detection
US5157020A (en) * 1990-05-24 1992-10-20 Research Corporation Tech., Inc. Synthetic senescent cell antigen
DK9091D0 (da) 1991-01-18 1991-01-18 Novo Nordisk As Fremgangsmaade til fremstilling af antistoffer
DE4120412C1 (de) * 1991-06-20 1993-01-07 Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin, De
US6322989B1 (en) * 1991-11-25 2001-11-27 Yoreh Biotechnologies, Ltd. Whole blood/mitogen assay for the early detection of a subject with ovarian or breast cancer and kit
US6280962B1 (en) * 1991-11-25 2001-08-28 Yoreh Biotechnologies Ltd. Whole blood/mitogen assay for the early detection of a subject with cancer and kit
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
US5753522A (en) * 1991-12-06 1998-05-19 Legacy Good Samaritan Hospital And Medical Center Purified protein for identifying a cancer-associated retinopathy autoantibody
JPH07505719A (ja) 1992-04-14 1995-06-22 デューク・ユニバーシティー ｐ５３及びＨＳＰ７０のコンプレックスを含む腫瘍の検出方法
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5763164A (en) * 1993-04-16 1998-06-09 Northwestern University Immunogenic cancer proteins and peptides and methods of use
US5747268A (en) * 1993-04-22 1998-05-05 Dade International Inc. Tumor marker control
US5744144A (en) * 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
US5721105A (en) * 1994-02-20 1998-02-24 B.R.A.H.M.S. Diagnostica Gmbh Method for the immunological determination of proteins and kit for carrying out the method
JPH07294530A (ja) 1994-04-20 1995-11-10 Nippon Igaku Rinshiyou Kensa Kenkyusho:Kk 病原体に対する体液中の抗体検出法
CA2148971A1 (en) 1994-05-26 1995-11-27 Izak Bahar Calibrator matrix
EP1018518A2 (de) 1994-06-24 2000-07-12 Vladimir P. Torchilin Verwendung von Autoantikörpern zur Tumorbehandlung und Vorbeugung
IL110464A0 (en) 1994-07-26 1994-10-21 Univ Ramot Novel proteins for the diagnosis, imaging, and therapy of human cancer
US5561049A (en) * 1994-09-21 1996-10-01 Behringwerke Ag Method for detecting antibodies
US5876728A (en) * 1995-02-15 1999-03-02 Howard David Kass Natural composition extracted from plants used in the treatment of cancer
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
GB9521544D0 (en) 1995-10-20 1995-12-20 Univ Dundee Activation of P53 protein and therapeutic applications thereof
JPH09189702A (ja) 1996-01-09 1997-07-22 Hitachi Chem Co Ltd 抗ムチン抗体の測定法、癌の測定法及び癌診断薬
AU3889997A (en) * 1996-08-16 1998-03-06 Johns Hopkins University School Of Medicine, The Melanoma cell lines expressing shared immunodominant melanoma antigens nd methods of using same
US8021666B2 (en) * 1997-02-18 2011-09-20 Sloan-Kettering Institute For Cancer Research Method and compositions for stimulation of an immune response to CD20 using a xenogeneic CD20 antigen
AU7713498A (en) 1997-06-03 1998-12-21 Amdl, Inc. Immunoassay for the detection of cancer
ATE266203T1 (de) * 1997-06-26 2004-05-15 Univ Michigan Methode zur identifizierung von tumorantigenen mit autoantikörpern in serum
DE19805815C1 (de) * 1998-02-13 1999-11-11 Ansgar W Lohse Diagnostikum zum Erkennen der autoimmunen Hepatitis
JP4083855B2 (ja) 1998-02-16 2008-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 肺癌予後検査方法
GB9810040D0 (en) * 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
AUPP349098A0 (en) 1998-05-13 1998-06-04 South Eastern Sydney Area Health Service A method of monitoring pancreatic tissue viability
GB9821170D0 (en) * 1998-09-30 1998-11-25 Univ Ulster Marker
AU767842B2 (en) * 1998-11-03 2003-11-27 Cell Genesys, Inc. Cancer-associated antigens and methods of their identification
CA2349593A1 (en) * 1998-11-05 2000-05-11 The Regents Of The University Of Michigan S100 proteins and autoantibodies as serum markers for cancer
US6387639B1 (en) * 1998-11-10 2002-05-14 Sloan-Kettering Institute For Cancer Research Ma family polypeptides and anti-Ma antibodies
GB9827228D0 (en) * 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
JP2000281255A (ja) * 1999-03-31 2000-10-10 Seiko Epson Corp 記録装置
US7807810B2 (en) * 1999-04-08 2010-10-05 The Ohio State University Research Foundation Nucleic acids encoding the major outer membrane protein of the causative agent of human granulocytic ehrlichiosis and peptides encoded thereby
US6645465B2 (en) * 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
US20020064801A1 (en) * 1999-12-01 2002-05-30 Ryan Jeffrey R. Novel and practical serological assay for the clinical diagnosis of leishmaniasis
US6667160B2 (en) * 2000-03-15 2003-12-23 Kenneth D. Fine Method for diagnosing immunologic food sensitivity
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
US20030138860A1 (en) * 2000-06-14 2003-07-24 Robertson John Forsyth Russell Cancer detection methods and reagents
US6379550B1 (en) * 2000-07-24 2002-04-30 Health Research, Inc. Method for detecting PSA and its molecular forms using thiophilic gel
CA2431201A1 (en) 2000-12-13 2002-08-01 Bio-Rad Laboratories, Inc. Standard diluent for multiplex assays
US7745141B2 (en) * 2001-06-21 2010-06-29 New York University Mycobacterial proteins as early antigens for serodiagnosis and vaccines
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20030049692A1 (en) * 2002-09-16 2003-03-13 Norman Latov Detection of anti-glycolipid antibodies by latex agglutination assay
GB2424273B (en) 2002-11-14 2007-06-27 Univ Nottingham Method for preparing tumour marker protein
JP2005352771A (ja) * 2004-06-10 2005-12-22 Hitachi Software Eng Co Ltd 発現プロファイルによるパターン認識システム
US20060141547A1 (en) * 2004-11-16 2006-06-29 Das Hasi R Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
EP1789435B1 (de) 2005-09-12 2010-02-24 Industry Foundation of Chonnam National University Verfahren zur herstellung einer voll entwickelten natürlichen killerzelle
TWI304443B (en) 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
US8574848B2 (en) * 2006-09-13 2013-11-05 Oncimmune Ltd. Immunoassay methods
CA2663154C (en) 2006-09-13 2016-02-23 Oncimmune Ltd Improved immunoassay methods
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay

Also Published As

Publication number Publication date
WO2004044590A1 (en) 2004-05-27
JP4759267B2 (ja) 2011-08-31
GB0604694D0 (en) 2006-04-19
GB2395270B (en) 2006-08-16
GB2424273A (en) 2006-09-20
GB2424070B (en) 2007-06-27
JP2006506612A (ja) 2006-02-23
ATE397217T1 (de) 2008-06-15
DK1563307T3 (da) 2008-09-29
AU2003282245B2 (en) 2010-05-20
EP1563307A1 (de) 2005-08-17
ES2305530T3 (es) 2008-11-01
PT1563307E (pt) 2008-07-16
GB0604693D0 (en) 2006-04-19
SI1563307T1 (sl) 2008-10-31
US20140080736A1 (en) 2014-03-20
GB2424070A (en) 2006-09-13
EP1563307B1 (de) 2008-05-28
AU2003282245A1 (en) 2004-06-03
US20060094069A1 (en) 2006-05-04
US8592169B2 (en) 2013-11-26
CA2545930A1 (en) 2004-05-27
CA2545930C (en) 2016-07-12
GB0226622D0 (en) 2002-12-24
GB2395270A (en) 2004-05-19
EP1967856A2 (de) 2008-09-10
CY1108294T1 (el) 2014-02-12
EP1967856A3 (de) 2009-04-15
GB2424273B (en) 2007-06-27

Similar Documents

Publication Publication Date Title
DE60321375D1 (de) Tumormarker proteine und deren verwendung
CY1105129T1 (el) Οπτικος αισθητηρας για την επι τοπου μετρηση αναλυομενων ουσιων
DE602006018578D1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
DE69930666D1 (de) Krebsnachweisverfahren und reagenzien
CY1109684T1 (el) Συστημα δοκιμης αναλυτη για τον προσδιορισμο της συγκεντρωσης ενος αναλυτη σε ενα φυσιολογικο ή υδατικο ρευστο
DK1078264T3 (da) Tumormarkörer
CY1105923T1 (el) Οπτικος αισθητηρας για επι τοπου μετρηση αναλυτων
DK1960771T3 (da) Sensorer
ATE400813T1 (de) Tumormarker für frühes krebsstadium
ATE493652T1 (de) Quantitative assays für pdgfr-beta- in körperflüssigkeiten
DE602005019694D1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
ATE357652T1 (de) Verfahren und vorrichtung für messungen im blut
CL2009000299A1 (es) Sistema optico y procedimiento para detectar la presencia de un elemento biologico vivo; sensor biometrico de identificador de personas.
WO2009019367A3 (fr) Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
FR2912423B1 (fr) Milieu de detection et/ou d'identification de bacteries
DK1853735T3 (da) Fremgangsmåder til detektering af progressionen af cervikal dysplasi i let grad
ATE555385T1 (de) N1,n12-diacetylspermin als tumormarker
WO2009019366A3 (fr) Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal
DE112007003222A5 (de) Prognostische Marker für die Klassifizierung von kolorektalen Karzinomen basierend auf Expressionsprofilen von biologischen Proben
ATE303451T1 (de) Nanopartikeln für optische sensoren
DE112007003223A5 (de) Prognostische Marker für die Klassifizierung des dreijährigen progressionsfreien Überlebens von Patienten mit kolorektalem Karzinom basierend auf Expressionsprofilen von biologischen Proben
Puchberger Sensor Systems for Impaired Healing Markers, Concepts and Applications for Objective Wound Assessment
RU2018105621A (ru) Способ диагностики рака предстательной железы
DE112007003238A5 (de) Prognostische Marker für die Vorhersage des fünfjährigen progressionsfreien Überlebens von Patienten mit kolorektalen Karzinomen basierend auf Expressionsprofilen von biologischen Proben

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: BEETZ & PARTNER PATENTANWAELTE, 80538 MUENCHEN

8364 No opposition during term of opposition